Is the Common Cold a Coronavirus or Rhinovirus?

The common cold is caused by both rhinoviruses and coronaviruses, along with several other virus families. Rhinoviruses are the dominant culprit, responsible for roughly half of all cold episodes, while four endemic coronaviruses collectively account for a smaller but meaningful share. The reason the question comes up so often is that the COVID-19 pandemic made “coronavirus” a household word, and many people were surprised to learn that a branch of that same virus family had been giving them the sniffles for decades. The reality is messier and more interesting than a simple either/or.

Rhinoviruses Are the Leading Cause, but Not the Only One

In a study that tested 200 adults presenting with common cold symptoms, a viral cause was identified in about 69% of cases. Rhinoviruses showed up in 105 of those patients, making them the single largest contributor. Coronaviruses (strains OC43 and 229E) were found in 17 patients, and influenza, parainfluenza, respiratory syncytial virus, adenovirus, and enterovirus accounted for the rest.¹ That roughly 50% figure for rhinoviruses has held up across many surveillance studies over the years, though the exact proportion shifts depending on the season and what else is circulating in a given community.

The remaining third or so of colds where no virus is identified is not a mystery gap filled by some unknown pathogen. It largely reflects the limits of testing. Some infections clear before sampling catches the virus, and older diagnostic methods simply missed certain strains. Modern molecular tools have narrowed that gap, but it has not disappeared entirely.

The Four “Common Cold” Coronaviruses

When people hear “coronavirus,” their minds jump to SARS-CoV-2. But coronaviruses are a large family, and four members have been circulating in humans for decades, possibly centuries. These are strains 229E, OC43, NL63, and HKU1. Researchers have proposed calling them “common cold coronaviruses,” or ccCoV, to distinguish them clearly from the pandemic-causing strains like SARS-CoV-2 and the original SARS and MERS viruses.²

Each of these four strains uses a different strategy to get inside your cells. Infection with 229E causes a drop in a surface protein called CD13, which it uses as an entry point. OC43 binds to a sugar molecule called GD3. NL63, interestingly, uses the same receptor that SARS-CoV-2 does: ACE2.³ That shared ACE2 receptor is one reason NL63 attracted scientific interest during the COVID-19 pandemic, even though NL63 itself typically causes nothing worse than a stuffy nose.

In healthy adults, these four coronaviruses produce colds that are essentially indistinguishable from rhinovirus colds by symptoms alone. You get the same runny nose, scratchy throat, and mild fatigue. The viruses differ in their molecular biology, but from your perspective as the person sneezing into a tissue, the experience is the same.

Why Rhinoviruses Are So Hard to Pin Down

Rhinoviruses are not one virus. They are a sprawling family of over 160 known types, divided into three species: A, B, and C.⁴ Each species uses a different protein on the surface of your airway cells to break in. The majority of A-type and all B-type rhinoviruses latch onto a protein called ICAM-1. Twelve A-type rhinoviruses use a receptor from the low-density lipoprotein family instead. And species C rhinoviruses use a protein called CDHR3.⁵

That diversity matters because it explains why you keep getting colds throughout your life. Catching one rhinovirus type gives you immunity to that specific type, but with more than 160 types circulating, your immune system is always meeting new ones. It also explains why building a vaccine has been so difficult, a point worth returning to later.

Rhinoviruses belong to the Picornaviridae family, which classifies them alongside enteroviruses (the family that includes poliovirus). They are tiny, non-enveloped RNA viruses. Coronaviruses, by contrast, are enveloped RNA viruses with a lipid coating, which is why soap and hand sanitizer work especially well against them: the soap dissolves the fatty envelope. The structural differences between the two families are substantial, even though the symptoms they produce overlap almost completely.

Why Different Viruses Cause the Same Symptoms

It seems counterintuitive that viruses with such different biology would all produce the same basic illness. The answer lies in how your body responds rather than in what the virus itself does. Cold symptoms are driven largely by your immune system’s reaction to infection, not by the virus directly destroying tissue. When a virus infects the lining of your nose and throat, your immune cells release signaling molecules called cytokines. Those cytokines trigger the runny nose, sore throat, sneezing, and that general feeling of being run down.⁶

Because the immune response is doing most of the symptom-making rather than the virus itself, a wide range of viruses that infect the same airway tissue can trigger nearly identical colds. This also helps explain why “treating a cold” mostly means managing inflammation and congestion rather than attacking the virus directly. Your body is already fighting the virus effectively; the misery comes from its battle tactics.

Seasonal Patterns Differ Between the Two

Rhinoviruses and common cold coronaviruses do not follow the same calendar. Research at the Common Cold Unit in Salisbury, one of the longest-running cold research programs, found that rhinovirus infections peak in autumn and spring, while coronavirus infections tend to cluster in winter and spring.⁷ Despite this difference, both produce clinically indistinguishable colds.

The autumn surge of rhinovirus colds is a familiar pattern to anyone with school-age children. When kids return to classrooms in September, rhinoviruses rip through the population. The seasonal mechanism involves temperature-dependent viral behavior: different strains adapt their ability to replicate at temperatures matching their local climate and season.⁸ Rhinoviruses replicate most efficiently at the slightly cooler temperatures found in the nasal passages (around 33-35°C), which is one reason they concentrate in the upper airways rather than the lungs.

Coronaviruses, meanwhile, tend to peak during the colder months, overlapping with influenza season. This means that in midwinter, your cold is statistically more likely to be a coronavirus than it would be in September, when rhinoviruses dominate. In the tropics, where temperature variation is smaller, respiratory viruses circulate at more constant levels year-round rather than in sharp seasonal waves.

When a “Simple Cold” Gets Complicated

For most healthy adults, a cold from either virus family resolves on its own in a week or so. But rhinoviruses in particular can cause real trouble for people with asthma. Rhinovirus infection is responsible for most asthma exacerbations in children and adolescents, and this risk increases when the person is also exposed to an allergen they are sensitized to.⁹ Genetic background also plays a role: some people’s immune systems respond to rhinovirus infection with more intense airway inflammation, which tips an otherwise mild infection into a full-blown asthma attack.

Rhinovirus species C, the most recently discovered group, has attracted particular attention in this context. Species C rhinoviruses use the CDHR3 receptor, and a genetic variant in the gene coding for that receptor has been linked to higher susceptibility to childhood asthma. So the specific doorway the virus uses to enter cells can have downstream consequences for disease severity, not just for whether you catch a cold.

Common cold coronaviruses can also cause serious illness in vulnerable people. A retrospective comparison of hospitalized patients with seasonal coronavirus infections found that these patients tended to be older (average age about 74) and most had multiple underlying health conditions.¹⁰ Even among hospitalized patients, COVID-19 produced more severe outcomes than seasonal coronaviruses, with higher rates of sepsis and acute respiratory distress syndrome. But the fact that seasonal coronaviruses land people in the hospital at all challenges the notion that they are always harmless.

Immunity Is Short-Lived for Both

One reason colds are so common is that immunity to the viruses that cause them does not last. Seasonal common cold coronaviruses are known to produce short-term protection against mild reinfection, while offering longer-lasting protection against severe reinfection.¹¹ In practical terms, you can catch the same coronavirus strain again within a year or two, though the second bout may be milder. Reinfection studies for endemic coronaviruses have documented people catching the same strain repeatedly over a span of several years.

For rhinoviruses, the problem is compounded by sheer variety. Even if your immunity to any single type lasted a lifetime, with over 160 types circulating, you would never run out of new ones to encounter. Adults catch an average of two to four colds per year, and children often get more than that. Most of these are rhinovirus infections, cycling through different types as the seasons turn.

Why There Is No Common Cold Vaccine

The diversity of cold-causing viruses is the central obstacle. Unlike measles or polio, where one or a handful of strains account for the disease, a successful cold vaccine would need to cover a staggering range of targets. For rhinoviruses alone, more than 150 serologically distinct types would need to be addressed, spanning three species, and the immune response to one type does not cross-protect against others.¹² Producing enough antigen to cover that breadth is a manufacturing nightmare, even before considering whether such a vaccine could stimulate a broad enough immune response.

There are no approved antiviral therapies specifically targeting rhinoviruses, and past vaccine strategies have failed because of this diversity and the lack of cross-protection between types.¹³ Researchers have explored targeting the conserved receptor-binding sites rather than the variable surface antigens, which could theoretically bypass the serotype problem. Some groups have also looked at multivalent vaccine approaches that mix dozens of rhinovirus types into one formulation. Progress has been made in the lab, but nothing has come close to clinical deployment.

For the common cold coronaviruses, the vaccine situation is slightly different. The four strains are antigenically more stable than rhinoviruses, but the mildness of the disease they cause has historically made it hard to justify the cost of development. A vaccine against a virus that gives you the sniffles for a week is a tough sell to funding agencies. The COVID-19 pandemic briefly renewed interest in broader coronavirus vaccines, but most of that effort focused on pandemic preparedness rather than on the endemic strains.

How Doctors Identify Which Virus You Have

In routine clinical practice, they usually do not. When you visit a doctor with cold symptoms, a diagnosis of “upper respiratory infection” is based on your symptoms and history, and no test is run to identify the specific virus. Treatment is the same regardless of the cause, so there is little clinical reason to test.

In research and hospital settings, the picture is different. Multiplex molecular tests can screen a nasal swab for a panel of respiratory viruses simultaneously. Systems like the FilmArray respiratory panel can detect influenza, RSV, adenovirus, and other pathogens in under an hour.¹⁴ More sensitive research-grade tests like MassTag-PCR have identified respiratory pathogens in over 60% of samples that had tested negative by older methods like viral culture, and they have been particularly useful in detecting newly recognized rhinovirus clades that traditional tests missed.¹⁵

This matters for surveillance. Knowing which viruses are circulating in a community helps public health officials distinguish a surge of rhinovirus colds from early influenza activity, which requires a very different response. For the individual patient with a sore throat and a box of tissues, though, the specific virus behind their cold remains an academic question.

Transmission and What Actually Helps

Both rhinoviruses and common cold coronaviruses spread through a combination of routes: respiratory droplets expelled by coughing and sneezing, smaller aerosol particles that linger in the air, direct person-to-person contact, and contaminated surfaces (fomites).¹⁶ Rhinoviruses can survive on hard surfaces for hours, which is why hand hygiene is one of the most effective preventive measures. Coronaviruses, with their fragile lipid envelope, tend to be somewhat less durable on surfaces but still transmit readily through close contact.

Because there is no vaccine and no targeted antiviral, managing a cold comes down to symptom relief and waiting it out. One intervention that has generated decades of back-and-forth is zinc. An early controlled trial found that zinc gluconate lozenges reduced symptom scores and nasal secretions in people experimentally infected with rhinovirus, with effects becoming significant by the second to fourth day of treatment.¹⁷ Subsequent research has been mixed, with some trials confirming a modest benefit and others showing none. The mechanism remains unclear. Zinc is one of those interventions where the evidence is real but noisy, and whether it helps you specifically on a given cold is genuinely uncertain.

Standard advice still applies: rest, fluids, and over-the-counter decongestants or pain relievers for comfort. Antibiotics do nothing against cold viruses and should not be prescribed unless a secondary bacterial infection develops, something that happens in a small minority of cases.

The COVID-19 Overlap Question

Since 2020, a practical concern has been whether a common cold might actually be COVID-19. The symptom overlap is real: both SARS-CoV-2 and the endemic respiratory viruses can produce a runny nose, sore throat, cough, and mild fatigue. The key differences tend to be in severity and the presence of features less common in ordinary colds, such as loss of smell, high fever, or shortness of breath, though mild COVID-19 can look identical to a regular cold.

NL63’s use of the ACE2 receptor, the same entry point SARS-CoV-2 uses, has raised questions about whether prior infection with NL63 might offer any cross-protective immunity against COVID-19. The evidence so far has been inconclusive. The two viruses are quite distant relatives despite sharing a receptor preference, and the antibodies produced against NL63 do not appear to neutralize SARS-CoV-2 reliably. Some studies found slightly lower COVID-19 severity in people with recent endemic coronavirus antibodies, but these findings have not been consistent enough to draw firm conclusions.

For the average person wondering whether their sniffle is a cold or COVID, the only reliable answer remains testing. Rapid antigen tests can distinguish SARS-CoV-2 from other respiratory viruses within minutes. If the test is negative and your symptoms are mild upper-airway congestion without fever, you are most likely dealing with a rhinovirus or one of the four endemic coronaviruses, depending on the time of year.